Metabolic effects of diphosphonate in primary hyperparathyroidism
| Autor: | Mark Haussler, Roy A. Kaplan, Charles Y.C. Pak, W. Blair Geho, Gerald W. Dietz, Carol Poindexter |
|---|---|
| Rok vydání: | 1977 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors endocrine system diseases Urinary system Parathyroid hormone chemistry.chemical_element Calcium Bone resorption Intestinal absorption Bone and Bones Phosphates Parathyroid Glands Internal medicine medicine Cyclic AMP Humans Pharmacology (medical) Aged Pharmacology Clinical Trials as Topic business.industry Hyperparathyroidism Diphosphonates Etidronic Acid Middle Aged medicine.disease Alkaline Phosphatase Urinary calcium Hydroxyproline Endocrinology chemistry Parathyroid Hormone Dihydroxycholecalciferols Female business Primary hyperparathyroidism |
| Zdroj: | Journal of clinical pharmacology. 17(7) |
| ISSN: | 0091-2700 |
| Popis: | Six patients with primary hyperparathyroidism (PHPT) and one with squamous cell carcinoma of the esophagus with parathyroid hormone excess received disodium ethane-1-hydroxy-1,1-diphosphonate (EHDP) at a daily dose of 20 mg/kg orally. During treatment, the decrease in urinary calcium, total urinary hydroxyproline, and fasting urinary calcium suggested an inhibition of bone resorption. Serum calcium intestinal absorption of calcium and urinary cyclic adenosine monophosphate (cAMP) did not change significantly. This preliminary study indicates a possible role of diphosphonates in the management of inoperable cases of primary hyperparathyroidism or pseudohyperparathyroidism. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text